A Genetic Variant in CD274 Is Associated With Prognosis in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Based Chemotherapy

Bevacizumab plus chemotherapy is a well-established first-line treatment for metastatic colorectal cancer (mCRC). We investigated whether polymorphisms of genes involved in immune regulation signaling are related to the clinical outcome of mCRC patients treated with bevacizumab-based chemotherapy. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Wan, Zhao, Ben, Wang, Duanrui, Liu, Jiamin, Zhou, Yilu, Zhu, Wenjun, Huang, Yongbiao, Qiu, Hong, Yuan, Xianglin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275392/
https://www.ncbi.nlm.nih.gov/pubmed/35837092
http://dx.doi.org/10.3389/fonc.2022.922342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275392/
https://www.ncbi.nlm.nih.gov/pubmed/35837092
http://dx.doi.org/10.3389/fonc.2022.922342

Ejemplares similares